1月8日，威士顿盘中上涨2.06%，截至13:24，报61.84元/股，成交2.51亿元，换手率11.14%，总市值 54.42亿元。 截至11月30日，威士顿股东户数1.80万，较上期减少4.37%；人均流通股2054股，较上期增加4.56%。 2025年1月-9月，威士顿实现营业收入1.22亿元，同比减少32.34%；归母净利润2148.59万元，同比减少 28.30%。 分红方面，威士顿A股上市后累计派现6600.00万元。 责任编辑：小浪快报 资料显示，上海威士顿信息技术股份有限公司位于上海市长宁区淮海西路666号1602室，成立日期2001 年5月17日，上市日期2023年6月21日，公司主营业务涉及主营业务可划分为软件开发、运维服务、系统 集成、软件产品及服务。根据应用领域的不同,发行人业务主要涵盖智能制造、数字化金融等方面。主 营业务收入构成为：软件开发43.04%，运维服务24.89%，软件产品销售及服务19.63%，系统集成 10.75%，其他1.69%。 威士顿所属申万行业为：计算机-软件开发-横向通用软件。所属概念板块包括：数字孪生、数字经济、 AIAgent（智能体）、ERP概念、人工 ...

威士顿今年以来股价涨3.97%，近5个交易日涨4.50%，近20日跌10.33%，近60日涨20.56%。 资料显示，上海威士顿信息技术股份有限公司位于上海市长宁区淮海西路666号1602室，成立日期2001 年5月17日，上市日期2023年6月21日，公司主营业务涉及主营业务可划分为软件开发、运维服务、系统 集成、软件产品及服务。根据应用领域的不同,发行人业务主要涵盖智能制造、数字化金融等方面。主 营业务收入构成为：软件开发43.04%，运维服务24.89%，软件产品销售及服务19.63%，系统集成 10.75%，其他1.69%。 1月6日，威士顿盘中上涨2.10%，截至09:53，报59.45元/股，成交7264.32万元，换手率3.35%，总市值 52.32亿元。 资金流向方面，主力资金净流入247.66万元，特大单买入511.20万元，占比7.04%，卖出319.28万元，占 比4.40%；大单买入1170.99万元，占比16.12%，卖出1115.26万元，占比15.35%。 截至11月30日，威士顿股东户数1.80万，较上期减少4.37%；人均流通股2054股，较上期增加4.56%。 2025年1 ...

最新公告列表 《北京宝兰德软件股份有限公司关于获得政府补助的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年12月12日收盘，宝兰德（688058）报收于26.6元，较前一交易日下跌0.23%，最新总市值为 20.68亿元。该股当日开盘26.6元，最高27.08元，最低26.51元，成交额达2655.28万元，换手率为 1.28%。 公司近日发布公告称，北京宝兰德软件股份有限公司近日收到政府补助款项1,000万元，属于与收益相 关的政府补助。根据《企业会计准则第16号——政府补助》的规定，该补助将对公司经营业绩产生一定 积极影响。具体会计处理及对损益的影响需以审计机构年度审计确认结果为准。 ...

Group 1 - The core viewpoint of the news is that Yangpu Medical has shown a significant increase in stock price and trading activity, indicating positive market sentiment and potential investment interest [1][2]. - As of November 12, Yangpu Medical's stock price rose by 2.06% to 8.41 CNY per share, with a total market capitalization of 2.6 billion CNY and a trading volume of 24.99 million CNY [1]. - The company has experienced a year-to-date stock price increase of 52.36%, with a 2.69% rise over the last five trading days and a 9.65% increase over the last 20 days, although it has seen a decline of 7.89% over the last 60 days [1]. Group 2 - Yangpu Medical's main business involves providing technical solutions, products, and services for clinical testing laboratories and clinical care, with revenue composition as follows: vacuum blood collection systems (66.48%), reagents (12.23%), software products and services (10.03%), testing services (5.10%), other products (3.23%), instruments (2.81%), and microbiological transport systems (0.12%) [1]. - As of September 30, the company reported a total revenue of 349 million CNY for the first nine months of 2025, a year-on-year decrease of 17.14%, while the net profit attributable to shareholders was 24.04 million CNY, reflecting a year-on-year increase of 156.55% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 79.13 million CNY since its A-share listing [3].

Core Viewpoint - The stock price of Weiston has experienced a decline of 22.86% year-to-date, but has shown recent recovery with an increase of 8.43% over the last five trading days [2] Group 1: Stock Performance - As of October 29, Weiston's stock price rose by 2.15% to 52.37 CNY per share, with a trading volume of 1.11 billion CNY and a turnover rate of 5.90%, resulting in a total market capitalization of 4.609 billion CNY [1] - Year-to-date, Weiston's stock has been on the龙虎榜 (top trading list) nine times, with the most recent appearance on June 27, where it recorded a net purchase of 72.16 million CNY [2] Group 2: Financial Performance - For the period from January to September 2025, Weiston reported a revenue of 122 million CNY, representing a year-on-year decrease of 32.34%, while the net profit attributable to shareholders was 21.49 million CNY, down 28.30% year-on-year [3] - The company has distributed a total of 66 million CNY in dividends since its A-share listing [4] Group 3: Business Overview - Weiston, established on May 17, 2001, and listed on June 21, 2023, is based in Shanghai and specializes in software development, operation and maintenance services, system integration, and software products and services [2] - The main revenue composition includes software development (43.04%), operation and maintenance services (24.89%), software product sales and services (19.63%), system integration (10.75%), and other services (1.69%) [2] - Weiston operates within the computer software development industry and is associated with concepts such as fintech, internet finance, data elements, small-cap stocks, and ERP concepts [2] Group 4: Shareholder Information - As of September 30, Weiston had 13,200 shareholders, a decrease of 12.20% from the previous period, with an average of 2,803 circulating shares per shareholder, an increase of 13.90% [3]

Core Viewpoint - Yangpu Medical's stock has shown significant growth this year, with a 47.64% increase, despite a decrease in revenue for the first nine months of 2025 [1][2]. Group 1: Stock Performance - As of October 28, Yangpu Medical's stock price increased by 2.13% to 8.15 CNY per share, with a trading volume of 17.79 million CNY and a turnover rate of 0.81%, resulting in a total market capitalization of 2.52 billion CNY [1]. - The stock has experienced a net inflow of 1.04 million CNY from main funds, with large orders accounting for 13.76% of purchases and 7.93% of sales [1]. - The stock has risen by 3.56% in the last five trading days, 5.03% in the last 20 days, and 0.12% in the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yangpu Medical reported a revenue of 349 million CNY, a year-on-year decrease of 17.14%, while the net profit attributable to shareholders was 24.04 million CNY, reflecting a year-on-year increase of 156.55% [2]. - The company has distributed a total of 79.13 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 28,500, a rise of 16.74%, while the average number of circulating shares per person decreased by 14.34% to 9,550 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A is the ninth largest shareholder with 1.17 million shares, marking its entry as a new shareholder [3].

Core Viewpoint - Yangpu Medical's stock price has shown a significant increase of 42.21% year-to-date, indicating strong market performance despite recent fluctuations [2]. Company Overview - Yangpu Medical Technology Co., Ltd. was established on August 19, 1996, and listed on December 25, 2009. The company is located in Zhuhai, Guangdong Province, and primarily provides technical solutions, products, and services for clinical testing laboratories and clinical care [2]. - The company's revenue composition includes: vacuum blood collection systems (66.48%), reagents (12.23%), software products and services (10.03%), testing services (5.10%), other products (3.23%), instruments (2.81%), and microbiological transport systems (0.12%) [2]. Stock Performance - As of October 21, Yangpu Medical's stock price reached 7.85 CNY per share, with a trading volume of 28.23 million CNY and a turnover rate of 1.34%, resulting in a total market capitalization of 2.43 billion CNY [1]. - The stock has experienced a net inflow of 527,800 CNY from main funds, with large orders accounting for 10.60% of purchases and 8.73% of sales [1]. Financial Performance - For the first half of 2025, Yangpu Medical reported a revenue of 231 million CNY, a year-on-year decrease of 21.22%. However, the net profit attributable to shareholders increased by 389.40% to 15.27 million CNY [2]. - The company has not distributed any dividends in the past three years, with a total payout of 79.13 million CNY since its A-share listing [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 5.76% to 24,400, with an average of 11,149 circulating shares per person, an increase of 11.13% [2]. - Notable institutional holdings include Huaxia CSI 500 Index Enhanced A (007994) as the fifth largest shareholder, increasing its stake by 3.60 million shares, and new entrants such as Huaxia Zhisheng Pioneer Stock (LOF) A (501219) and Huaxia CSI 500 Index Smart Enhanced A (013233) [3].

Core Points - The stock price of Weiston increased by 2.00% to 47.36 CNY per share as of October 20, with a market capitalization of 4.168 billion CNY [1] - Weiston's stock has declined by 30.24% year-to-date, with a 3.25% drop over the last five trading days [1] - The company has appeared on the trading leaderboard nine times this year, with the most recent net buy of 72.16 million CNY on June 27 [1] Company Overview - Weiston, established on May 17, 2001, is located in Changning District, Shanghai, and was listed on June 21, 2023 [1] - The company's main business includes software development, operation and maintenance services, system integration, and software products and services [1] - Revenue breakdown: software development (43.04%), operation and maintenance services (24.89%), software product sales and services (19.63%), system integration (10.75%), and others (1.69%) [1] Financial Performance - For the first half of 2025, Weiston reported revenue of 91.6953 million CNY, a year-on-year decrease of 29.17%, and a net profit of 16.1298 million CNY, down 22.65% year-on-year [2] - The total cash distributed by Weiston since its A-share listing amounts to 66 million CNY [3] Shareholder Information - As of September 30, Weiston had 13,200 shareholders, a decrease of 12.20% from the previous period, with an average of 2,803 circulating shares per shareholder, an increase of 13.90% [2]

Group 1 - On September 23, the stock of Weston fell by 3.08%, with a trading volume of 91.72 million yuan [1] - The financing data on the same day showed that Weston had a financing purchase amount of 6.86 million yuan and a financing repayment of 11.63 million yuan, resulting in a net financing outflow of 4.77 million yuan [1] - As of September 23, the total balance of margin trading for Weston was 140 million yuan, which accounts for 7.47% of its circulating market value, indicating a low financing balance compared to the past year [1] Group 2 - As of August 29, the number of shareholders of Weston was 15,000, a decrease of 2.65% from the previous period, while the average circulating shares per person increased by 2.72% to 2,461 shares [2] - For the first half of 2025, Weston reported an operating income of 91.70 million yuan, a year-on-year decrease of 29.17%, and a net profit attributable to shareholders of 16.13 million yuan, down 22.65% year-on-year [2] Group 3 - Since its A-share listing, Weston has distributed a total of 66 million yuan in dividends [3]

Group 1 - The core viewpoint of the news is that Yangpu Medical has seen a stock price increase of 5.14%, reaching 8.18 yuan per share, with a total market capitalization of 2.529 billion yuan as of the report date [1] - Yangpu Medical specializes in providing technical solutions, products, and services for clinical testing laboratories and clinical care, with its main business revenue composition being 66.48% from vacuum blood collection systems, 12.23% from reagents, and 10.03% from software products and services [1] - The company is located in Zhuhai, Guangdong Province, and was established on August 19, 1996, with its listing date on December 25, 2009 [1] Group 2 - From the perspective of fund holdings, Penghua Fund has one fund heavily invested in Yangpu Medical, specifically the Penghua Smart Investment Digital Economy Mixed A fund, which reduced its holdings by 3,180 shares in the second quarter [2] - The fund currently holds 21,100 shares of Yangpu Medical, representing 0.62% of the fund's net value, ranking as the eighth largest holding [2] - The Penghua Smart Investment Digital Economy Mixed A fund has achieved a year-to-date return of 38.26% and a one-year return of 86.81%, ranking 1303 out of 8180 and 549 out of 7978 respectively [2]